CRISPR stocks begin to converge in the clinic: Data Byte

CRISPR Therapeutics’ stock price is still more than twice that of its closest gene editing peers, but the picture has started to shift over the past year as other companies have entered the clinic. 

CRISPR Therapeutics AG (NASDAQ:CRSP) began to diverge in share price from the other publicly traded gene editing companies in Feb. 2019 after dosing the first patient with a CRISPR-edited stem cell therapy, and it’s been outperforming its peers since. The current valuation of the Phase I/II company is over $11 billion. ...